CD19 and diffuse large B-cell lymphoma: In a small study with an in-house developed tandem CD19/CD22 4-1BB-z CART for DLBCL (n=21), 4 out of 14 patients had CD19-negative tumors at relapsing while preserving CD22 antigen expression (96).